Treatment of a 12-Hour Shift of Sleep Schedule with Benzodiazepines
SciencePublished 15 June 1984
Wesley F. Seidel, Thomas Roth, Timothy Roehrs, Frank Zorick, William C. Dement
Citations85
SJR quartileQ1
SJR score10.42
SNIP6.62
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Despite good sleep, flurazepam subjects appeared most impaired of the three groups on objective assessments of waking function; triazolam subjects were least impaired.
Abstract
Normal sleepers underwent sleep recordings and daytime tests of sleep tendency, performance, and mood while being shifted 180 degrees in their sleep-wake schedule. After two baseline 24-hour periods, subjects postponed sleep until noon. For the next three 24-hour periods, they were in bed from 1200 to 2000 and received triazolam, flurazepam, or placebo at bedtime in parallel groups. Placebo subjects showed significant sleep loss after the shift. Active medication reversed this sleep loss. Despite good sleep, flurazepam subjects appeared most impaired of the three groups on objective assessments of waking function; triazolam subjects were least impaired.
Keywords
PsychologyNeuroscience
PsychophysiologyQuantification of Sleepiness: A New Approach
2,555 Citations1973Eric Hoddes, Vincent P. Zarcone +3 more
British Journal of Clinical PharmacologyPsychomotor function and psychoactive drugs.
534 Citations1980I. Hindmarch
A cursory review of the literature reveals that the techniques used to assess psychomotor functions are diverse, often complex, frequently insensitive to drug induced changes and sometimes inconvenient to enact or replicate.
Electroencephalography and Clinical NeurophysiologyExcessive daytime sleepiness in man: Multiple sleep latency measurement in narcoleptic and control subjects
458 Citations1978Gary S. Richardson, Mary A. Carskadon +4 more
It is concluded that the Multiple Sleep latency test, in addition to providing opportunities to clinically document sleep onset REM sleep periods, can demonstrate pathological sleepiness.
PsychopharmacologySedative-hypnotics and human performance
209 Citations1982Laverne C. Johnson, DORIS A. CHERNIK
Although long-acting drugs generally showed more performance decrement, half-life data were not consistent, and, in comparing active drug to placebo, it is clear that all hypnotics, at some doses, produce decrements in performance the next day.
Clinical Pharmacology & TherapeuticsKinetics and clinical effects of flurazepam in young and elderly noninsomniacs
151 Citations1981David J. Greenblatt, Marcia Divoll +3 more
Clinical self‐ratings indicated increases over time in perception of morning sedation; changes slowly reverted to baseline in the week after dosage, and there was no evidence of increased sensitivity to FLZ in the elderly.
Clinical Pharmacology & TherapeuticsTriazolam disposition
142 Citations1981F S Eberts, Y Philopoulos +2 more
The results are consistent with the short duration of action of T‐14C, and nonconjugated α‐HT and 4‐HT were present in plasma but in insufficient amounts for kinetic analysis.
SLEEPDaytime Carryover of Triazolam and Flurazepam in Elderly Insomniacs
129 Citations1982Mary A. Carskadon, Wesley F. Seidel +2 more
It is suggested that, although both compounds improve nocturnal sleep in elderly insomniacs, there is significant residual sedation with flurazepam and improved daytime alertness with triazolam.
Archives of NeurologyAcute Reversal of the Sleep-Waking Cycle in Man
127 Citations1970Elliot D. Weitzman
The changes in sleep pattern when normal young adults were subjected to an acute inversion of sleep-waking cycles in man are described.
Journal of Clinical PsychopharmacologyComparative Hypnotic Effects of Flurazepam, Triazolam, and Placebo
98 Citations1984Merrill M. Mitler, Wesley F. Seidel +3 more
Daytime testing revealed significantly decreased daytime alertness and decreased performance for flurazepam subjects during weeks 3 to 7, although these effects reverted toward baseline despite continued drug administration, suggesting that the onset of the rebound insomnia depended on the rate of drug washout.
British Journal of Clinical PharmacologyResidual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam.
90 Citations1976K Seppala, K. Korttila +2 more
The lack of alterations in adaptation to darkness, sensitivity to brightness or visual discrimination ability in bright counterlight at a time when flicker fusion discrimination was severely depressed suggests that an impaired ability to discriminate flickering light is of no or little clinical significance to driving ability.
PubMedDoxepin and cimetidine in the treatment of duodenal ulcer: an open clinical and endoscopic study.
82 Citations1982T. E. Ruud, Geir Hoff +2 more
Buspirone failed to impair objective performance but caused drowsiness and fatigue, and the reference drug lorazepam impaired skills objectively, with less subjective impairment.
SLEEPDaytime Sleepiness as a Criterion in Hypnotic Medication Trials: Comparison of Triazolam and Flurazepam
50 Citations1983Donald L. Bliwise, Seidel Wesley +5 more
The use of daytime sleepiness, as assessed by the Multiple Sleep Latency Test (MSLT), as a criterion for daytime functioning in hypnotic medication trials is introduced, to indicate that daytimeSleepiness is a concomitant effect of flurazepam.